BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 15627885)

  • 21. [CEA, CA 19.9 and CA 195 in patients with colorectal carcinoma. ROC analysis].
    Vallejo J; Torres-Avisbal M; Contreras P; Rodríguez-Liñán M; Rebollo A; González F; Benítez A; Infante J; Mateo A
    Rev Esp Med Nucl; 1999 Aug; 18(4):281-6. PubMed ID: 10481111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
    Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
    Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The utility and prognostic value of CA 19-9 and CEA serum markers in the long-term follow up of patients with colorectal cancer. A single-center experience over 13 years.
    Tumay V; Guner OS
    Ann Ital Chir; 2020; 91():494-503. PubMed ID: 32990277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer.
    Yin LK; Sun XQ; Mou DZ
    Asian Pac J Cancer Prev; 2015; 16(9):3867-70. PubMed ID: 25987051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological characteristics.
    Mourtzikou A; Stamouli M; Kroupis C; Christodoulou S; Skondra M; Kastania A; Pectasides D; Athanasas G; Dimas C
    Clin Lab; 2012; 58(5-6):441-8. PubMed ID: 22783573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
    Yang XQ; Chen C; Wang FB; Peng CW; Li Y
    Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
    Knychalski B; Lukieńczuk T
    Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer.
    Lindmark G; Bergström R; Påhlman L; Glimelius B
    Br J Cancer; 1995 May; 71(5):1090-4. PubMed ID: 7734306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis.
    Körner H; Söreide K; Stokkeland PJ; Söreide JA
    Ann Surg Oncol; 2007 Feb; 14(2):417-23. PubMed ID: 17103264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].
    Grotowski M
    Pol Merkur Lekarski; 2002 Jan; 12(67):77-80. PubMed ID: 11957811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.
    Pectasides D; Mylonakis A; Kostopoulou M; Papadopoulou M; Triantafillis D; Varthalitis J; Dimitriades M; Athanassiou A
    Am J Clin Oncol; 1997 Aug; 20(4):348-53. PubMed ID: 9256887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer Antigens (CEA and CA 19-9) as Markers of Advanced Stage of Colorectal Carcinoma.
    Vukobrat-Bijedic Z; Husic-Selimovic A; Sofic A; Bijedic N; Bjelogrlic I; Gogov B; Mehmedovic A
    Med Arch; 2013 Dec; 67(6):397-401. PubMed ID: 25568506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
    Panagiotidis E; Datseris IE; Rondogianni P; Vlontzou E; Skilakaki M; Exarhos D; Bamias A
    Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preliminary evaluation of clinical utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in stomach cancer.
    Gwak HK; Lee JH; Park SG
    Asian Pac J Cancer Prev; 2014; 15(12):4933-8. PubMed ID: 24998567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance.
    Hing JX; Mok CW; Tan PT; Sudhakar SS; Seah CM; Lee WP; Tan SM
    Breast; 2020 Aug; 52():95-101. PubMed ID: 32485607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.